Nocdurna (desmopressin orally disintegrating tablets) is an antidiuretic that contains desmopressin, a structural analogue of the natural pituitary hormone arginine vasopressin.
The drug works by stimulating vasopressin receptors in the kidneys, causing increased water re-absorption that helps in reducing urine production.
Ferring Canada general manager Michael Seckler said: "The availability in pharmacies of Nocdurna, the first low-dose format of desmopressin indicated in Canada for the treatment of nocturia in adults, expands treatment options for healthcare providers and is good news for patients for whom behavior and lifestyle changes have not been effective in reducing the frequency of waking up for nighttime urination."
Nocturia is commonly experienced due to underlying medical conditions such as overactive bladder (OAB) and benign prostatic hyperplasia (BPH).
In Phase III trials, Nocdurna showed consistent, significant efficacy by several measures that translated into clinical benefits for patients.
According to the company, the recommended dose of Nocdurna is 25 mcg in women and 50mcg in men one hour before bedtime.